J W Hay

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
    J W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, USA
    Pharmacoeconomics 15:47-74. 1999
  2. ncbi request reprint Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom
    M F Botteman
    Pharmerit North America LLC, Bethesda, MD, USA
    Rheumatology (Oxford) 46:1320-8. 2007
  3. doi request reprint Using pharmacoeconomics to value pharmacotherapy
    J W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics, and Policy, University of Southern California, Los Angeles, California, USA
    Clin Pharmacol Ther 84:197-200. 2008
  4. ncbi request reprint Economic burden of haematological adverse effects in cancer patients: a systematic review
    S Y Liou
    Pharmerit North America LLC, Bethesda, Maryland 20814, USA
    Clin Drug Investig 27:381-96. 2007

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
    J W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, USA
    Pharmacoeconomics 15:47-74. 1999
    ..But any proven opportunity for saving the lives of 25% of those dying from cardiovascular disease each year deserves to be considered with the utmost seriousness and urgency...
  2. ncbi request reprint Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom
    M F Botteman
    Pharmerit North America LLC, Bethesda, MD, USA
    Rheumatology (Oxford) 46:1320-8. 2007
    ..This study evaluated the cost effectiveness of adalimumab vs conventional therapy in patients with active ankylosing spondylitis (AS)...
  3. doi request reprint Using pharmacoeconomics to value pharmacotherapy
    J W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics, and Policy, University of Southern California, Los Angeles, California, USA
    Clin Pharmacol Ther 84:197-200. 2008
    ....
  4. ncbi request reprint Economic burden of haematological adverse effects in cancer patients: a systematic review
    S Y Liou
    Pharmerit North America LLC, Bethesda, Maryland 20814, USA
    Clin Drug Investig 27:381-96. 2007
    ..The objective of this review was to summarise the published literature on the economic burden of neutropenia, thrombocytopenia and anaemia as AEs of cancer treatment...